...
首页> 外文期刊>Human vaccines & immunotherapeutics. >A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease
【24h】

A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease

机译:表达核蛋白的克里米亚-刚果出血热(CCHF)病毒疫苗具有免疫原性,但不能赋予对致命疾病的保护

获取原文
获取原文并翻译 | 示例
           

摘要

Crimean-Congo Hemorrhagic Fever (CCHF) is a severe tick-borne disease, endemic in many countries in Africa, the Middle East, Eastern Europe and Asia. Between 15-70% of reported cases are fatal with no approved vaccine available. In the present study, the attenuated poxvirus vector, Modified Vaccinia virus Ankara, was used to develop a recombinant candidate vaccine expressing the CCHF virus nucleoprotein. Cellular and humoral immunogenicity was confirmed in 2 mouse strains, including type I interferon receptor knockout mice, which are susceptible to CCHF disease. Despite the immune responses generated post-immunisation, the vaccine failed to protect animals from lethal disease in a challenge model.
机译:克里米亚-刚果出血热(CCHF)是一种由tick传播的严重疾病,在非洲,中东,东欧和亚洲的许多国家中都很流行。在没有批准的疫苗的情况下,报告的病例中有15-70%是致命的。在本研究中,减毒痘病毒载体修饰的痘苗病毒安卡拉被用于开发表达CCHF病毒核蛋白的重组候选疫苗。在2只易患CCHF疾病的小鼠品系中证实了细胞和体液的免疫原性,包括I型干扰素受体敲除小鼠。尽管免疫后产生了免疫反应,但该疫苗未能在攻击模型中保护动物免受致死性疾病的侵害。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号